Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 7,201–7,300 of 15,747
Pattni, K., Hungerford, D., Adams, S., Buchan, I. E., Cheyne, C. P., García‐Fiñana, M., Hall, I., Hughes, D. M., Overton, C. E., Zhang, X. N., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07239-z · Cited by 11
“, 2020 [30], where the efficacy reported is lower for the 1st dose of the Pfizer-BioNTech vaccine.”
BackgroundResultRamsay, J. A., Jones, M. A., More, A. M. V., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.050 · Cited by 9
Bürzle, O., Menges, D., Maier, J. D., Schams, D., Puhan, M. A., Fehr, J. S., Ballouz, T., & Frei, A. L. (2023) · npj Vaccines · doi:10.1038/s41541-023-00657-3 · Cited by 10
Chew, C. K., Wang, R., Bavanandan, S., Zainudin, N., Zhao, X., Ahmed, S., Nair, D., Hou, L., Yahya, R., Ch’ng, S. S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-01003-x · Cited by 13
COVID-19 Vaccines in Children with Cow’s Milk and Food Allergies
Liotti, L., Bianchi, A., Bottau, P., Caimmi, S. M. E., Crisafulli, G., Franceschini, F., Mori, F., Paglialunga, C., Saretta, F., & Caffarelli, C. (2021) · Nutrients · doi:10.3390/nu13082637 · Cited by 12
“, anaphylaxis) to any component” of their vaccine [23,25].”
BackgroundNutritional Behavior in European Countries during COVID-19 Pandemic—A Review
Wiśniewski, O. W., Czyżniewski, B. J., Żukiewicz-Sobczak, W. A., & Gibas-Dorna, M. (2023) · Nutrients · doi:10.3390/nu15153451 · Cited by 11
Brownstein, J. S., Cantor, J., Rader, B. M., Simon, K. I., & Whaley, C. (2022) · National Bureau of Economic Research · doi:10.3386/w30429 · Cited by 14
COVID-19 Vaccine Evolution and Beyond
Brice, Y., Morgan, L., Kirmani, M., Kirmani, M., & Udeh, M. C. (2023) · Neuroscience Insights · doi:10.1177/26331055231180543 · Cited by 13
Mittal, D., & Ali, S. A. (2022) · Microbial Drug Resistance · doi:10.1089/mdr.2021.0281 · Cited by 10
The new UK SARS-CoV-2 variant and lockdown – causes and consequences
Pan, D., Mudalige, N. L., Sze, S., Koeckerling, D., Oyefeso, O., Barker, J., Williams, C., Tang, J. W.-T., & Pareek, M. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0019 · Cited by 9
Cationic nanoparticles-based approaches for immune tolerance induction in vivo
Mao, K., Wang, J., Xie, Q., Yang, Y., Shen, S., Sun, T., & Wang, J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.044 · Cited by 13
Safety of Monkeypox Vaccine Using Active Surveillance, Two-Center Observational Study in Italy
Montalti, M., Valerio, Z. D., Angelini, R., Bovolenta, E., Castellazzi, F., Cleva, M., Pandolfi, P., Reali, C., Resi, D., Todeschini, R., et al. (2023) · Vaccines · doi:10.3390/vaccines11071163 · Cited by 11
One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening
Urdániz, I. M. F., Steiner, P. J., Kirby, M. B., Zhao, F.-Z., Haas, C. M., Barman, S., Rhodes, E. R., Peng, L., Sprenger, K., Jardine, J., et al. (2021) · bioRxiv · doi:10.1101/2021.03.15.435309 · Cited by 41
Bruni, A., Longhini, F., Macheda, S., Biamonte, E., Pasqua, P., Neri, G., Guzzo, M. L., Garofalo, E., & Calabria COVID-ICU Network authors (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1042411 · Cited by 9
“The first cycle of vaccination with BNT162b2 vaccine consists in two consecutives mRNA doses administered 21 days apart (9),and it induces an efficient immune response in 95% of naïve individuals (10).”
BackgroundAn Update on Self-Amplifying mRNA Vaccine Development
(2020) · doi:10.20944/preprints202012.0452.v1 · Cited by 10
Dong, W., Miao, Y., Shen, Z., Zhang, W., Bai, J., Zhu, D., Ren, R., Zhang, J., Wu, J., Tarimo, C. S., et al. (2024) · JMIR Public Health and Surveillance · doi:10.2196/50595 · Cited by 9
Clinical trial research on COVID-19 in Germany – a systematic analysis
Hirt, J., Rasadurai, A., Briel, M., Düblin, P., Janiaud, P., & Hemkens, L. G. (2021) · F1000Research · doi:10.12688/f1000research.55541.1 · Cited by 8
COVID-19 and Central Nervous System Hypersomnias
Frange, C., Oliveira, G. D. P., & Coelho, F. M. S. (2022) · Current Sleep Medicine Reports · doi:10.1007/s40675-022-00226-5 · Cited by 11
Case Report: Two Case Reports of Acute Myopericarditis After mRNA COVID-19 Vaccine
Sciaccaluga, C., D’Ascenzi, F., Cameli, M., Gallotta, M., Menci, D., Antonelli, G., Banchi, B., Mochi, V., Valente, S., & Focardi, M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.827237 · Cited by 11
Shoji, K., Funaki, T., Yamada, M., Mikami, M., Miyake, K., Ueno, S., Tao, C., Myojin, S., Aiba, H., Matsui, T., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.09.013 · Cited by 10
“A multinational placebo-controlled trial of BNT162b2 in adults showed favorable outcomes with 95% efficacy for COVID-19 prevention and a low incidence of serious adverse events [3].”
BackgroundFactors influencing adverse events following COVID-19 vaccination
Villanueva, P., McDonald, E. A., Croda, J., Croda, M. G., Dalcolmo, M. P., dos Santos, G., Jardim, B. A., Lacerda, M., Lynn, D. J., Marshall, H. S., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2323853 · Cited by 11
The Impact of COVID-19 Pandemic on Lung Cancer Community
Wu, L., Zhang, C., & Zhao, X. (2021) · World Journal of Oncology · doi:10.14740/wjon1367 · Cited by 10
Updates on the coronavirus disease 2019 vaccine and consideration in children
Kang, H. M., Choi, E. H., & Kim, Y. (2021) · Korean Journal of Pediatrics · doi:10.3345/cep.2021.00696 · Cited by 10
McCune, T. R., Bray, R. A., Baran, D. A., et al. (2022) · Transplant Immunology · doi:10.1016/j.trim.2022.101722 · Cited by 10
Immune thrombocytopenic purpura cases following COVID-19 vaccination.
Condorelli, A., Markovic, U., Sciortino, R., et al. (2021) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2021.047 · Cited by 10
Baral, P., Ahmed, T., Fernandez, P. A., Peters, M. A., Drouard, S. H. P., Muhoza, P., Mwinnyaa, G., Mwansambo, C. W., Nzelu, C. E., Tassembedo, M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288124 · Cited by 11
“While vaccine trial data has shown that severe side effects are quite rare [25, 26], further reinforcing the importance of availaibility of safety data availability, our findings suggest that among the small pool of vaccine hesitant HCWs, concerns about side effects were prevalent across the six countries.”
BackgroundmRNA therapeutics beyond vaccines: dosing precision challenges and clinical translation framework
Niazi, S. K. (2026) · RSC Pharmaceutics · doi:10.1039/d5pm00159e · Cited by 19
The paradox of trust in health care in the age of social media
Ienca, M., Gounder, C. R., & Emanuel, E. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02556-5 · Cited by 16
(2021) · doi:10.1101/2021.11.11.21265536 · Cited by 41
Hitchon, C. A., Mesa, C., Bernstein, C. N., Marrie, R. A., Card, C. M., O’Brien, S. F., & Kim, J. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-071397 · Cited by 13
Tan, T. T., Ng, H. J., Young, B. E., Khan, B. A., Shetty, V., Azmi, N. A., & Clissold, S. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2191716 · Cited by 12
Antibody response to double SARS-CoV-2 mRNA vaccination in Japanese kidney transplant recipients
Fujieda, K., Tanaka, A., Kikuchi, R., Takai, N., Saito, S., Yasuda, Y., Fujita, T., Kato, M., Furuhashi, K., & Maruyama, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-10510-7 · Cited by 10
Sripongpun, P., Pinpathomrat, N., Bruminhent, J., & Kaewdech, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.924454 · Cited by 11
“6%) of 30,351 participants received the Pfizer and Moderna vaccines, respectively (75, 76).”
BackgroundResultKamura, Y., Sakamoto, T., Yokoyama, Y., Nishikii, H., Sakata‐Yanagimoto, M., Chiba, S., & Obara, N. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03387-9 · Cited by 14
Real-Time, Continuous Monitoring of Tissue Chips as an Emerging Opportunity for Biosensing
Cognetti, J. S., & Miller, B. L. (2025) · Sensors · doi:10.3390/s25165153 · Cited by 14
“For example, the Phase III clinical trial for the Pfizer/BioNTech mRNA vaccine for COVID-19 used over 43,000 subjects [16].”
Lipid-based Non-viral Vector: Promising Approach for Gene Delivery
Panday, A., Dixena, B., Jain, N. S., & Jain, A. K. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128324084240828084904 · Cited by 12
Ren, Z., Zhou, J., Yang, D., Guo, Y., Zhang, J., Xu, J., & Chen, Y. E. (2026) · Cells · doi:10.3390/cells15020134 · Cited by 15
“…gaps between phospholipids, boosting nanoparticle stability, integrity, and membrane fusion during cell entry and intracellular trafficking; and (iv) PEG-lipids are coated on nanoparticle surface, reducing aggregation, improving particle stability and half-life and lowering immunogenicity [77].”
Short term blood pressure alterations in recently COVID-19 vaccinated patients
Sanidas, E. A., Anastasiou, T., Papadopoulos, D., Velliou, M., & Mantzourani, M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.11.017 · Cited by 10
Maziec, K., Baliga-Gil, A., & Kierzek, E. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102572 · Cited by 15
“110,111,186 This vaccine has also received approval for use from the EMA.”
Darade, A. R., Lapteva, M., Hoffmann, T., Mandler, M., Schneeberger, A., & Kalia, Y. N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010151 · Cited by 12
“The vaccine, administered intramuscularly, was found to be 95% effective in preventing SARS-CoV-2 (COVID-19) in Phase 3 clinical trials [29,30].”
BackgroundLangowski, M. D., Francica, J. R., Roederer, A. L., Hurlburt, N. K., Rodarte, J. V., Pereira, L. D. S., Flynn, B. J., Bonilla, B. G., Dillon, M., Kiyuka, P. K., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01140-x · Cited by 13
Kuo, H., Kuo, K.-C., Du, P.-X., Keskin, B. B., Su, W., Ho, T., Tsai, P.-S., Pau, C. H., Shih, H.-C., Huang, Y., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100507 · Cited by 12
ALL-IN meta-analysis: breathing life into living systematic reviews
ter Schure, J., & Grünwald, P. (2022) · F1000Research · doi:10.12688/f1000research.74223.1 · Cited by 25
“Just as well as stating that the Pfizer/BioNTech trial (Polack et al., 2020) multiplied =C1 to almost =C118 million and the CureVac AG (2021) trial multiplied =C1 to =C1.”
InfluentialThyroid autoimmunity and SARS-CoV-2 infection: Report of a large Italian series
Fallahi, P., Ferrari, S. M., Elia, G., Paparo, S. R., Patrizio, A., Balestri, E., Mazzi, V., Gragnani, L., Ferri, C., Botrini, C., et al. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103183 · Cited by 11
“In a short time, numerous sera have been released [3], including, for the first time, mRNA technology based vaccines (Pfizer-Biontech’s BNT162b2 and Moderna’s mRNA-1273) [4,5].”
BackgroundSuccess of nano-vaccines against COVID-19: a transformation in nanomedicine
Sarangi, M. K., Padhi, S. K., Rath, G., Nanda, S. S., & Yi, D. K. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2148659 · Cited by 13
“LNP vaccines could be successful against emerging variants of SARS-CoV-2 [81,82], contradicting the necessity for additional formulation along with adjuvants [72,73].”
BackgroundFiori, M., Bello, G., Wschebor, N., Lecumberry, F., Ferragut, A., & Mordecki, E. (2022) · Scientific Reports · doi:10.1038/s41598-022-10896-4 · Cited by 11
Efficient Gene Editing for Heart Disease via ELIP-Based CRISPR Delivery System
Yin, X., Harmancey, R., Frierson, B., Wu, J. G., Moody, M. R., McPherson, D. D., & Huang, S. L. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030343 · Cited by 13
Key considerations for a prostate cancer mRNA vaccine
Lin, G., Elkashif, A., Saha, C., Coulter, J. A., Dunne, N., & McCarthy, H. O. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104643 · Cited by 14
Shortening Epitopes to Survive: The Case of SARS-CoV-2 Lambda Variant
Pascarella, S., Ciccozzi, M., Bianchi, M., Benvenuto, D., Giovanetti, M., Cauda, R., & Cassone, A. (2021) · Biomolecules · doi:10.3390/biom11101494 · Cited by 10
“Through the unprecedented outflow of technological, monetary, and human resources, some efficacious and safe anti-SARS-CoV-2 vaccines have been rapidly developed (in less than one year) and proven to be safe and effective in clinical trials and real-world use [1].”
BackgroundPurswani, M. U., Bucciarelli, J., Tiburcio, J., Yagudayev, S., Connell, G. H., Omidiran, A. A., Hannaway, L., Zeana, C. B., Healy, M., Yu, G., et al. (2021) · Journal of Hospital Medicine · doi:10.12788/jhm.3627 · Cited by 12
Dude, C. M., Joseph, N. T., Forrest, A. D., Verkerke, H., Cheedarla, N., Govindaraj, S., Irby, L. S., Easley, K. A., Smith, A. K., Stowell, S. R., et al. (2023) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14648 · Cited by 11
COVID-19 and risk of long-term mortality in COPD: a nationwide population-based cohort study
Lee, H. J., Kim, S. H., Jeong, C. Y., et al. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002694 · Cited by 10
Myasthenia gravis with ocular symptoms following a ChAdOx1 nCoV-19 vaccination: A case report
Kang, M. C., Park, K., Min, J., & Oh, S. Y. (2022) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2022.101620 · Cited by 10
Helmy, S. A., Morsi, R. M. E., Helmy, S. A. M., & El-Masry, S. M. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103762 · Cited by 15
Vaccines on demand, part II: future reality
Geall, A. J., Kis, Z., & Ulmer, J. B. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2147501 · Cited by 10
“protection from symptomatic COVID-19 disease [17] and real-”
BackgroundOptimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic
Ouali, S. E., Rubin, D. T., Cohen, B. L., Regueiro, M. D., & Rieder, F. (2021) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000741 · Cited by 10
Monteiro, H. S., Neto, A. S. L., Kahn, R. J., de Sousa, G. D. S., Carmona, H. A., Andrade, J. S., & Castro, M. C. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.065 · Cited by 11
Cancer nanotechnology: a new approach to upgrade cancer diagnosis and therapy
Rad, D. M., Nazari, H., Naei, V. Y., Lotfi, M., Aref, A. R., & Warkiani, M. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15518-5.00013-6 · Cited by 16
Kim, N., Shin, S., Minn, D., Park, S., An, D., Park, J. H., Roh, E. Y., Yoon, J. H., & Park, H. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac035 · Cited by 10
Hocaoğlu, R., Zıkşahna, K., & Ihlamur, M. (2026) · Health Nanotechnology · doi:10.1186/s44301-026-00026-8 · Cited by 15
Larsen, E. S., Nilsson, A. C., Möller, S., Voss, A., & Johansen, I. S. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/b8a6zb · Cited by 12
Tan, E., & Salman, S. (2022) · American Journal of Case Reports · doi:10.12659/ajcr.937212 · Cited by 10
“The Pfizer-BioNTech COVID-19 vaccine (BNT162b2) is a modified ribonucleic acid vaccine encoding the SARS-CoV2 full-length spike protein delivered in a lipid nanoparticle, which has demonstrated significant vaccine efficacy [4].”
BackgroundCOVID-19 Vaccine Effectiveness at a Referral Hospital in Northern Peru: A Retrospective Cohort Study
Valladares-Garrido, M. J., Zeña-Ñañez, S., Peralta, C. I., Puicón-Suárez, J. B., Díaz-Vélez, C., & Failoc‐Rojas, V. E. (2022) · Vaccines · doi:10.3390/vaccines10050812 · Cited by 14
“over, after two shots, during an interval of 21 days [9].”
BackgroundPerrotta, A., Biondi‐Zoccai, G., Saade, W., Miraldi, F., Morelli, A., Marullo, A. G. M., Cavarretta, E., Carnevale, R., FALCO, E. D., Chimenti, I., et al. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.21.04435-9 · Cited by 12
Nowill, A. E., Caruso, M., & de Campos-Lima, P. O. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133225 · Cited by 12
“The table was compiled from references (9) (NCT04368728) (10), (NCT04470427) (3), (ISRCTN89951424, NCT04400838) (6), (NCT04456595) (7), (NCT04508075) (8), (NCT04582344), and (11) (NCT04510207), as well as (4, 12–14).”
SARS-CoV-2 Targets and COVID-19 Vaccines
Currier, A. W., Jeshurin, M. C., & Sampson, V. B. (2021) · COVID · doi:10.3390/covid1030051 · Cited by 14
“Clinical trial data from the UK, Brazil, and South Africa show that after full vaccination, although the Oxford-AstraZeneca chimpanzee adenovirus-vectored ChAdOx1 nCoV-19 vaccine (AZD1222) has an acceptable safety profile, lower neutralizing antibody responses were induced [41] in comparison to other types of vaccines…”
BackgroundMartinot, M., Carnein, S., Kempf, C., Gantner, P., Gallais, F., & Fafi‐Kremer, S. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.06.038 · Cited by 10
“[3], possibly related to the age of the LTCF patients reported with natural immunity which, although effective in preventing COVID-19, is lower in older people [4].”
BackgroundLung directed antibody gene transfer confers protection against SARS-CoV-2 infection
Du, Y., Miah, K. M., Habib, O., Meyer‐Berg, H., Conway, C. C., Viegas, M., Dean, R., Satyapertiwi, D., Zhao, J., Wang, Y., et al. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-217650 · Cited by 9
COVID-19 Epidemiology, Immunity, and Vaccine Development in Children: A Review
FERGIE, J. E., Moran, M. M., Cane, A. D., Pather, S., Türeci, Ö., & Srivastava, A. K. (2022) · Vaccines · doi:10.3390/vaccines10122039 · Cited by 11
Self-citationReview: Unravelling the Role of DNA Sensing in Alum Adjuvant Activity
Gatt, Z., Gunes, U., Raponi, A., da Rosa, L. C., & Brewer, J. M. (2022) · Discovery Immunology · doi:10.1093/discim/kyac012 · Cited by 10
“More recently, novel platform technologies, such as RNA vaccines and adenovirus-vectored vaccines, have been applied in the SARS-CoV-2 pandemic response [11, 12].”
Outcomes associated with SARS-CoV-2 reinfection in individuals with natural and hybrid immunity
Suleyman, G., Fadel, R. A., Patel, K., Shadid, A. M., Stuart, H. B. C., Kattula, M., Janis, A., Maki, M., Chao, S., Alangaden, G. J., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.06.003 · Cited by 11
“o Vaccines against COVID-19 have been shown to reduce the risk of SARS-CoV-2 infection and severe COVID19, including severe illness, hospitalization and death, in randomized clinical trials and real-world observational studies [14,15,28,34].”
Infantino, M. G., Manfredi, M., Stacchini, L., Cosma, C., Grossi, V., Lari, B., Russo, E., Amedei, A., Benucci, M., Veneziani, F., et al. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0170 · Cited by 11
“After positively assessing the safety and efficacy of Pfizer/BioNT BNT162b2mRNA vaccine [4], approved by the European Medicines Agency (EMA) {Agency, an Italian vaccination campaign started on 27 December 2020, targeting firstly healthcare workers (HCWs)}, to ensure their protection and safety worldwide [5].”
BackgroundMontastruc, J., Biron, P., & Sommet, A. (2021) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12715 · Cited by 9
“The first vaccines to be marketed were the Pfizer tozinameran Comirnaty® [1] and Moderna [2] mRNA vaccines, followed by the adenovirus vaccines from AstraZeneca (Vaxzevria®) [3] and Janssen (Ad26.”
MethodTwo Modes of Th1 Polarization Induced by Dendritic-Cell-Priming Adjuvant in Vaccination
Seya, T., Shingai, M., Kawakita, T., & Matsumoto, M. (2023) · Cells · doi:10.3390/cells12111504 · Cited by 10
Effectiveness of COVID-19 vaccination during pregnancy by circulating viral variant
Zerbo, O., Ray, G. T., FIREMAN, B. H., Layefsky, E., Goddard, K., Ross, P., Greenberg, M., & Klein, N. P. (2023) · AJOG Global Reports · doi:10.1016/j.xagr.2023.100264 · Cited by 10
Amano, M., Otsu, S., Uemura, Y., Ichikawa, Y., Matsumoto, S., Higashi‐Kuwata, N., Matsushita, S., Shimada, S., & Mitsuya, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-44484-x · Cited by 10
Consensus statement and recommendations on the treatment of COVID-19: 2021 update
Ko, H.-K., Yu, W.-K., Pan, S., Chen, W.-C., Yang, K.-Y., Lin, Y.-T., Wang, F.-D., Yang, M.-H., & Chen, Y.-M. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000617 · Cited by 12
(2005) · Radiopaedia.org · doi:10.53347/rid-73913 · Cited by 15
A systematic analysis of biotech startups that went public in the first half of 2021
Huayamares, S. G., Lokugamage, M. P., Sanchez, A. J. D. S., & Dahlman, J. E. (2022) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2022.09.004 · Cited by 16
Guzmán‐López, S., Darwich-Salazar, A., Bocanegra‐Ibarias, P., Treviño, D. S., Flores-Treviño, S., Pérez-Alba, E., Nuzzolo-Shihadeh, L., Pérez‐Rodríguez, E., & Camacho-Ortíz, A. (2022) · Vaccines · doi:10.3390/vaccines10050656 · Cited by 10
“This may be one of the causes why breakthrough infection reports are higher in the reported literature than they were in our study (5% for Pfizer/BioNTech and 26% for AstraZeneca/Oxford) [25,26].”
ResultInfluentialHuang, W., Hernandez, I., Tang, S., Dickson, S., Berenbrok, L. A., & Guo, J. S. (2023) · BMC Research Notes · doi:10.1186/s13104-023-06366-3 · Cited by 11
Real‐world, single‐center experience of SARS‐CoV‐2 vaccination in immune thrombocytopenia
Woolley, P., Tailor, A., Shah, R., Westwood, J., & Scully, M. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15704 · Cited by 10
Rodríguez, C., Pérez-Nieva, A., Máiz, L., Meijon-Ortigueira, M. D. M., Llamas, P., Monréal, M., Bikdeli, B., & Jiménez, D. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.10.002 · Cited by 10
Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection
Yathindranath, V., Safa, N. A., Tomczyk, M. M., Dolinsky, V. W., & Miller, D. W. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s448005 · Cited by 10
“3,13 Several monoclonal antibody (mAb) based decoys were developed for neutralizing a wide range of HIV variants.”
BackgroundLuczkowiak, J., Labiod, N., Rivas, G. A., Rolo, M., Lasala, F., Lora‐Tamayo, J., Mancheño‐Losa, M., Rial, D., Pérez‐Rivilla, A., Folgueira, M. D., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab468 · Cited by 10
(2021) · doi:10.1101/2021.05.24.21257738 · Cited by 843
“664 OR = Odds ratio; CI = Confidence interval; IMD[1-3] = high deprivation, IMD[8-10] = low deprivation; reference category for IMD is the intermediate category IMD [4-7] All the univariate models are adjusted by age, BMI, and sex, except Not obese that is adjusted by only age and sex”
BackgroundMethodInfluentialSoegiarto, G., Wulandari, L., Purnomosari, D., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4008922 · Cited by 10
Theel, E. S. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.10.006 · Cited by 10
“It is clear that both natural infection and vaccination are associated with protection for at least 6 to 9 months; however, it is also evident, as discussed earlier, that antibody titers can be quite variable among individuals, in both their levels and persistence.(15,16,34,45) Once such a threshold is established and…”
BackgroundZhao, J., Xu, R., Lu, T., Wang, J., & Zhang, L. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1113 · Cited by 10
“mRNA vaccines do not integrate into the genome and can also be degraded by mRNA enzymes in vivo with good long-term safety (9,17), and their safety has also been confirmed in the process of counteracting coronavirus disease 2019 (18).”
BackgroundOverheu, O., Lendowski, S., Quast, D. R., Marheinecke, C. S., Kourti, E., Lugnier, C., Andreica, I., Kiltz, U., Pfaender, S., & Reinacher‐Schick, A. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04099-7 · Cited by 10
Corcorran, M. A., Austin, E. J., Behrends, C. N., Briggs, E. S., Frost, M. C., Juarez, A. M., Frank, N. D., Healy, E., Prohaska, S. M., LaKosky, P. A., et al. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001036 · Cited by 11
Yong, S. J., Kenny, T., Halim, A., Munipalli, B., Alhashem, Y. N., AlSaihati, H., Al‐Subaie, M. F., Kaabi, N. A., Fares, M. A. A., Garout, M. A., et al. (2025) · Reviews in Medical Virology · doi:10.1002/rmv.70070 · Cited by 14
Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein
Borocci, S., Cerchia, C., Grottesi, A., Sanna, N., Prandi, I. G., Abid, N., Beccari, A. R., Chillemi, G., & Talarico, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115464 · Cited by 9
“Among these vaccines, both Pfizer/BioNTech and Moderna use mRNA encoding for the S glycoprotein [3,4] while Gamaleya Sputnik V [5], Oxford/AstraZeneca [6], and CanSino [7] vaccines are based on adenoviruses, as vectors encoding for the full-length S glycoprotein.”
MethodNext-generation COVID-19 vaccines: here come the proteins
Blakney, A. K., & McKay, P. F. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00258-0 · Cited by 10
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.